372 related articles for article (PubMed ID: 17195414)
1. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
Ahmed MM; Mubashir E; Wolf RE; Hayat S; Hall V; Shi R; Berney SM
South Med J; 2006 Nov; 99(11):1209-15. PubMed ID: 17195414
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
[TBL] [Abstract][Full Text] [Related]
3. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Greiner A; Plischke H; Kellner H; Gruber R
Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
[TBL] [Abstract][Full Text] [Related]
4. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
[TBL] [Abstract][Full Text] [Related]
5. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
6. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.
Vis M; Bos WH; Wolbink G; Voskuyl AE; Twisk JW; Van de Stadt R; Hamann D; Dijkmans BA; Lems WF
J Rheumatol; 2008 Mar; 35(3):425-8. PubMed ID: 18322974
[TBL] [Abstract][Full Text] [Related]
7. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.
Jaskowski TD; Hill HR; Russo KL; Lakos G; Szekanecz Z; Teodorescu M
J Rheumatol; 2010 Aug; 37(8):1582-8. PubMed ID: 20516016
[TBL] [Abstract][Full Text] [Related]
8. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
Mikuls TR; O'Dell JR; Stoner JA; Parrish LA; Arend WP; Norris JM; Holers VM
Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
[TBL] [Abstract][Full Text] [Related]
9. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
10. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
[TBL] [Abstract][Full Text] [Related]
11. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
12. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
13. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
15. Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis.
Krol A; Garred P; Heegaard NH; Christensen AF; Hetland ML; Stengaard-Pedersen K; Junker P; Madsen HO; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Pedersen JK; Svendsen AJ; Tarp U; Pødenphant J; Lindegaard H; Østergaard M; Hørslev-Petersen K; Jacobsen S
Scand J Rheumatol; 2015; 44(1):8-12. PubMed ID: 25205362
[TBL] [Abstract][Full Text] [Related]
16. Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheumatoid factor and anti-cyclic citrullinated peptide antibody.
Atta AM; Carvalho EM; Jerônimo SM; Sousa Atta ML
J Autoimmun; 2007 Feb; 28(1):55-8. PubMed ID: 17257811
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
Caramaschi P; Biasi D; Tonolli E; Pieropan S; Martinelli N; Carletto A; Volpe A; Bambara LM
Rheumatol Int; 2005 Nov; 26(1):58-62. PubMed ID: 15726373
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis.
Nikolaisen C; Rekvig OP; Nossent HC
Scand J Rheumatol; 2007; 36(2):97-100. PubMed ID: 17476614
[TBL] [Abstract][Full Text] [Related]
20. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
